Pfizer/Eyetech Macugen ASP
Executive Summary
Pfizer/Eyetech's Macugen reimbursed at $1,054.70 per injection under Medicare Part B average sales price plus 6% model. Macugen, which FDA approved Dec. 17 for the treatment of neovascular (wet) age-related macular degeneration, carries a list price of $995 per injection (1"The Pink Sheet" Jan. 3, 2005, p. 7). Labeling recommends Macugen be administered every six weeks, bringing the treatment's annual cost based on list price to $7,960 per eye, and CMS' annual reimbursement per eye to $8,437.60 (2"The Pink Sheet" Jan. 10, 2005, p. 20)...
You may also be interested in...
Macugen Access Program Will Help Seniors With Medicare Copay
The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
QUOTED. 25 February 2021. Adam Saltman.
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: